

## **Value of the intellectual property portfolio of Genomtec S.A. estimated at EUR 191.336 million**

**Genomtec S.A., a company from the medical technology industry, specializing in the development of advanced technologies in the field of genetic diagnostics, received from the German company Dennemeyer Consulting GmbH a valuation of the Company's intellectual property portfolio. According to the DIN/ISO 77100 standard adopted by Dennemeyer, covering 9 patents held by Genomtec and 26 patent applications, as well as the conversion of all patent applications into patents, as well as a 14-year protection period for the entire IP (intellectual property) portfolio, the fair value of Genomtec's intellectual property was estimated at EUR 191.336 million.**

Dennemeyer Consulting GmbH, adopting a conservative, only 8-year patent protection period, valued the Company's portfolio of intellectual property rights at EUR 95.663 million. This valuation assumes a discount on patent applications currently being processed, and if the current 100% success rate of conversion of patent applications into patents is maintained, this value will increase to EUR 109.335 million. The average term of patent protection of Genomtec's petitioners is over 15 years.

*- In our opinion, the valuation of the Genomtec intellectual property rights portfolio estimated by Dennemeyer corresponds to its fair value. We currently hold 9 patents in Europe, USA and Japan and over 26 patent pending applications in global markets. Our portfolio of patents and patent applications is young and gradually growing. It should also be remembered that the presented valuation concerns only intellectual property and does not take into account aspects such as manufactured products, technical diagrams, Team, received certificates and admission to trading - said Miron Tokarski, CEO and Co-founder of Genomtec S.A. - Together with our transaction advisor Clairfield Partners LLC, we continue the process of establishing strategic partnerships, selling licenses and/or selling all or part of Genomtec's intellectual property – said CEO.*

Dennemeyer is a renowned global provider of legal services for patents, trademarks, data verification, project execution, litigation support audits, and other intellectual property portfolio management services. Dennemeyer is an entity with more than 60 years of tradition and 20 regional offices located on 6 continents, cooperating with entities such as Airbus, L'oreal, Boehringer Ingelheim and Gedeon Richter.

As part of Genomtec's review of strategic options on November 30, 2022. The company has signed an agreement with Clairfield Partners LLC based in New York. The subject of the agreement is consultancy in the process of establishing a strategic partnership, selling licenses and/or selling all or part of the intellectual property and related technology. Clairfield has extensive experience in M&A transactions in the area of medical technology and biotechnology, including genetic diagnostics.

---

**Genomtec:**

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The solution uses microfluidic technology and proprietary patented SNAAT isothermal technology. The Genomtec technology is protected by a total of 9 patents in Europe, USA and Japan, and over 26 patent applications on global markets.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The company's registered office is located in Wrocław. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.

More information is available on the [Company's](http://www.genomtec.com) website: [www.genomtec.com](http://www.genomtec.com)

**Media Contact:**

Kamil Majcher

NewTech Comm

[k.majcher@newtechcomm.pl](mailto:k.majcher@newtechcomm.pl)

+48 507 649 596

By gaining access to press releases ("Press Releases") of Genomtec S.A. with its registered office in Wrocław ("Company") and reading their content, you acknowledge and agree to be bound by the following reservations and conditions:

The Company's Press Releases are for promotional and informational purposes only and should under no circumstances constitute the basis for making a decision to purchase the Company's shares.

The Press Releases have been prepared by the Company for informational purposes only, and none of the provisions contained therein constitutes any recommendation regarding the purchase of shares, does not constitute an offer to sell the Company's securities or information on the terms of their acquisition or subscription constituting a sufficient basis for making a decision to purchase or subscribe for these securities, and none of the provisions contained therein constitutes investment advice, legal or tax, nor is it an indication that any investment or strategy is appropriate to the individual circumstances of the investor.

Investing in the Company's securities is associated with high risk inherent in equity capital market instruments and risks related to the Company's operations and the environment in which the Company operates.

All rights to the Press Releases and to their individual elements, including proprietary copyrights, are vested in the Company. In addition, the Company indicates that the reproduction, distribution, transmission or making available of the Press Releases may be subject to legal restrictions (restrictions and their scope may vary from jurisdiction to jurisdiction) and any person to whom the Press Releases are provided or otherwise made available should familiarize themselves with such restrictions and strictly comply with them. The Press Releases, or any part thereof, may not be distributed in the United States of America, Canada, Australia or Japan or to U.S. Persons.

Persons reviewing the Press Releases also represent that they are not covered by the applicable laws of any jurisdiction in which the display, distribution or publication of materials contained in the Press Releases would be prohibited or would require appropriate permission or permission.

The Press Releases are for informational purposes only and do not constitute an offer to sell securities or an offer to obtain an offer to buy securities or any other instruments or shares in the Company or any other undertaking.

The Press Releases also do not constitute an offer to cooperate on any other terms, or an offer to sell or an invitation to submit offers to buy, or subscriptions for shares of the Company or any other securities of either the Company or third parties. The content of the Press Releases does not constitute, and will not be incorporated by reference, any agreement between the Company and any third party, nor shall it give rise to any obligations of the Company, persons acting on behalf of the Company or persons to whom it is made available. Persons to whom the Press Releases are made available should not rely on them in connection with any contract, obligation, or intention of any other action relating to the Company.

The Press Releases do not contain a complete or complete financial or commercial analysis of the Company. The Press Releases do not represent a complete or comprehensive analysis of the Company's position or prospects. Press releases have been prepared with due diligence and attention to the quality of information

contained therein, however, there is a risk of inaccuracies as well as omission of some information. Any decisions concerning the Company should be made on the basis of independently conducted analyses and research. Persons who have read the Press Releases bear full responsibility for their possible assessment of the Company's situation and forecasts of its future development.

In the event that the Press Releases contain forward-looking content or statements, including analyses regarding the possible or expected future financial or commercial results of the Company, each such statement or content is subject to risk. The risk referred to in the preceding sentence consists of both factors known and unknown to the Company. Due to the possibility of a significant number of unforeseen events and other factors that may cause the actual financial results of the Company as well as the situation in the industry in which the Company operates, to the extent that they contain statements regarding the future. Nothing in the Press Releases should be construed as a guarantee or assurance or commitment that the Company will achieve any particular financial or commercial performance in the future.

The Company, its members of its bodies and directors, as well as shareholders, advisors or representatives of the Company make no express or implied representations, warranties or warranties as to the accuracy, completeness, correctness of the information and content contained in the Press Releases, or that in no event can any such content or information mislead the recipient. The Press Releases and the content contained therein have not been verified by entities independent of the Company. To the fullest extent permitted by law, the liability of the persons indicated above for any statements, content or statements contained in the Press Releases is excluded, including for any damage that could be caused by compliance with these statements, content or statements by persons to whom the Press Releases have been made available.

No statement contained in the Press Releases results in any of the indicated entities incurring any obligation. The Company, members of its bodies and management as well as shareholders, advisors, representatives of the Company are exempt from liability for any consequences of the use of information, data or statements contained in the Press Release, or any part thereof, regardless of the manner and purpose of such use. All responsibility for the use of any information contained in the Press Releases rests with the person using such information. Any information, statement or analysis regarding the future may be changed by the Company or their representatives at any time without prior notice of such change. The Company, members of its bodies and management as well as shareholders, advisors, representatives of the Company are not obliged to update the Press Releases in the event of any changes or to provide the recipients of the Press Releases with any additional information.

Nothing contained herein or in the Press Releases constitutes any recommendation regarding the purchase of shares or any other action having equivalent effects on the Company's shares or any other securities. None of the presented information constitutes forecasts, including but not limited to financial forecasts, and should not be interpreted as forecasts. This document or the Press Releases have not been approved or verified in any way by the Polish Financial Supervision Authority, and their content has not been audited or approved by the Warsaw Stock Exchange. Investment in shares involves a number of investment risks, therefore investors should carefully and thoroughly familiarize themselves with the risk associated with the Company's operations and the environment, in which the Company operates.